A Risk Prediction Model of Postoperative Nausea and Vomiting in Patients With Liver Cancer

Launched by SHANGHAI ZHONGSHAN HOSPITAL · Apr 5, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on creating a better risk prediction model for postoperative nausea and vomiting (PONV) in patients with liver cancer who undergo surgery. PONV can be a common issue after surgery, and understanding who is at higher risk can help doctors provide better care and improve recovery. The goal is to update existing models to make them more effective for patients with liver cancer, allowing for personalized treatment plans.

To participate in this trial, you must be at least 18 years old and diagnosed with liver cancer, specifically planning to have surgery to remove part of the liver (called a hepatectomy). It’s important to note that people with certain conditions, like cognitive impairments or nausea related to other diseases, won’t be eligible. If you join the study, researchers will evaluate your risk for nausea and vomiting after surgery, which may help in developing better prevention strategies for future patients. The trial is not yet recruiting participants, so there will be more information available soon for those interested.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who are diagnosed with liver cancer and underwent hepatectomy
• • Patients who are older than 18 years
• • Patients who have planned admissions and elective surgery, and stay at least 24 hours in the surgical unit.
• Exclusion Criteria:
• • Patients with cognitive impairment
• • Patients with nausea and vomiting related to other existing diseases, such as gastroesophageal reflux disease.
• • Patients with severe postoperative complications, including massive abdominal hemorrhage, hepatic encephalopathy and portal vein thrombosis.